A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double--Blind, 12-Week Study With a 40-Week, Active-Controlled, Open-Label Extension to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting Triglyceride Levels ≥500 mg/dL and <2000 mg/dL and Mild or Moderate Renal Impairment
Latest Information Update: 01 Nov 2022
At a glance
- Drugs Pemafibrate (Primary) ; Fenofibrate
- Indications Hypertriglyceridaemia
- Focus Therapeutic Use
- Sponsors Kowa Pharmaceutical; Kowa Research Institute
- 01 Oct 2019 Status changed from active, no longer recruiting to completed.
- 19 Jul 2019 This trial has been completed in Hungary, according to European Clinical Trials Database.
- 19 Jul 2019 This trial has been completed in Czech Republic , according to European Clinical Trials Database.